Mepolizumab for COPD Hospital Eosinophilic admissions Pragmatic trial
Chief Investigator: Prof Chris Brightling
Principal Investigator: Dr Neil Greening
COPD is a significant cause of illness and death worldwide and it is associated with acute exacerbations (sudden worsening or ‘flare ups’ of COPD symptoms) which can lead to hospitalisation. In some patients, the immune system produces abnormally high levels of a particular type of white blood cell, called eosinophils, which make the symptoms of COPD more severe. This is known as ‘eosinophilic COPD’.
This trial, COPD-HELP, is comparing mepolizumab, a medication currently being used to treat asthma, with a placebo (‘dummy drug’) with the aim of reducing the number of exacerbations in patients with eosinophilic COPD. The research team are interested in finding out whether mepolizumab reduces the chance of re-admission to hospital as well as death following a severe eosinophilic exacerbation of COPD.
Participants will be randomised to receive either mepolizumab or the placebo by injection under the skin. Participants will receive the treatment 12 times, once every 4 weeks, and will undergo a series of tests and assessments which aim to understand how the treatment they receive affects their health status, well-being and future exacerbations of COPD. They will then return for a final follow-up visit 4 weeks after the last dose.
238 participants will be recruited to this trial. As it is a placebo-controlled trial, half (119) will be allocated to receive mepolizumab, while the other half will receive placebo.
This is a single centre trial within our respiratory facility at Glenfield Hospital, led by Professor Chris Brightling and Dr Neil Greening. The trial is sponsored by the University of Leicester, co-ordinated by Leicester Clinical Trials Unit, and funded by GlaxoSmithKline.
The study is currently open to recruitment. For more information, please contact the local research team on the details below.
Dr Hamish McAuley: firstname.lastname@example.org
Dr Omer Elneima: email@example.com
Sue Parish: firstname.lastname@example.org
Trial management team at Leicester CTU: email@example.com